Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib salvage therapy for refractory celiac disease type II
NL-OMON52502Phase 2Recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tofacitinib in refractory celiac disease type II, sponsored by Vrije University Medical Center. Primary endpoint: Immunological response. Started Nov 2019; status: recruiting.
02
Drugs
03
Conditions
refractory celiac disease type II
Beyond the preview
Go deeper on NL-OMON52502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52502.